the Reinius lab

As a response to the ongoing COVID-19 pandemic we are currently investing major efforts into developing methods and procedures that improve the turn-around in COVID-19 diagnostics and that may simplify SARS-CoV-2 RNA-based tests. Read about our work on cheaper, faster COVID-19 testing: Massive and rapid COVID-19 testing is feasible by extractionfree SARS-CoV-2 RT-PCR (Nature Communications)

OUR RESEARCH aims to reveal fundamental features of gene regulation, and in particular the regulation of active versus inactive chromatin. Main topics of the lab are X-chromosome inactivation and dosage compensation. The X chromosome is a unique genetic environment. Female cells contain two X chromosomes while male cells contain one. To balance the X-gene dose in female cells one X copy is kept transcriptionally silenced by the process of X-chromosome inactivation. This is achieved by remarkable remodeling of the inactive X chromosome, which drastically alters its chromatin structure, methylation patterns, and three-dimensional conformation, ultimately suppressing the expression of most of its genes. By characterizing the epigenetic framework of X-chromosome inactivation, we may reveal key features of gene regulation and cellular systems. During the last years, Reinius and colleagues pioneered the use of single-cell RNA-seq in the study of X-inactivation (Science 2014, Nature Reviews Genetics 2015, Cell 2016, Nature Genetics 2016 etc., see Publications ). Currently the Reinius lab is working to determine the X-inactive landscape across a wide range of in vivo tissues and cell types. This is accomplished by a synthesis of newly developed concepts and techniques, including single-cell RNA-sequencing, chromatin accessibility and modification assays, mouse genetics and transgenics, and recently advanced computational methods for the analysis of allele-specific gene expression. The expected outcome of the research is of broad biomedical significance, and may reveal the regulatory underpinnings of variable expressivity and incomplete penetrance of X-linked genetic disorders.

- A MECHANISTIC BREAKTHROUGH: Recently, we have been studying X-chromosome upregulation using single-cell transcriptomics. The single active X-chromosome in both male and female cells cells becomes hyper activated to balance the gene dose with the diploid autosomal part of the genome. We discovered that this hyper activation is achieved by increased transcriptional burst frequencies for X-linked genes (article in Nature Structural & Molecular Biology 2019). This represents a Breakthrough to the Mechanism of Dosage Compensation. An excellent News & Views feature on this study is available here: Rapid transcriptional bursts upregulate the X chromosome, authored by Xinxian Deng & Christine M. Disteche.

Advancing RNA/DNA sequencing technology: High-throughput sequencing is key to our work, and is increasingly utilized in biomedicine. We are working to develop and improve methods for RNA and DNA sequencing, tailoring the methods to maximize information yield in the context of specific assays.

LOCATION: The Reinius lab is placed at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet, an international and vibrant research environment. Our Division, Biomaterials, is located at Biomedicum, KI Solna Campus, a purpose-built facility for experimental medical research. It hosts research groups with diverse backgrounds, from cell biology to biophysics, forming a unique interdisciplinary cluster of expertise in Molecular Biology and Biomedicine.

Karolinska Institutet, Solna, Stockholm